Please login to the form below

Not currently logged in
Email:
Password:

Combination treatment

This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.

GSK shares positive phase 3 results for Blenrep combination in multiple myeloma

GSK shares positive phase 3 results for Blenrep combination in multiple myeloma

GSK has shared positive results from a late-stage trial of its BCMA-targeting antibody-drug conjugate Blenrep (belantamab mafodotin) as a second-line treatment for relapsed or refractory multiple myeloma. ... The DREAMM clinical development programme

Latest news

More from news
Approximately 0 fully matching, plus 379 partially matching documents found.

Latest Intelligence

  • The impact of prostate cancer on global health The impact of prostate cancer on global health

    PME: With a number of similar drugs currently being developed for combination treatment with novel hormone agents used in prostate cancer, how has drug development for this disease improved in the ... It is therefore critical to research novel treatment

  • Tuberculosis – why it remains a major global public health challenge Tuberculosis – why it remains a major global public health challenge

    TB combination treatment regimens into phase 2 clinical development. ... The MRI will conduct non-clinical and clinical studies of these candidates to determine their potential for inclusion in new affordable combination treatment regimens for TB with

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin

  • Pharma deals in April 2015 Pharma deals in April 2015

    No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

  • Listening and hearing - how patients’ online behaviour can help us to improve wellbeing in psoriasis. Listening and hearing - how patients’ online behaviour can help us to improve wellbeing in psoriasis.

    Frequently raised concerns form patients include embarrassment and social anxiety in relation to their skin, and the positive impact that effective treatment can have in combination with maintaining good mental health.

  • What does the future hold for Light-chain Amyloidosis?

    approval in combination with CyBorD for the treatment of newly diagnosed adult patients with AL amyloidosis. ... Prior to the approval of a new combination treatment for use across Europe, we conducted the first wave of our research to generate a

  • Oncosec

    body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed

  • Marketing strategy in complex environments

    The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...